Metformin and Colorectal Cancer

Overview

Journal Front Endocrinol (Lausanne)

Specialty Endocrinology

Date 2018 Nov 9

PMID 30405532

Citations 21

Authors

Takuma Higurashi

Atsushi Nakajima

Affiliations

Soon will be listed here.

Abstract

Colorectal Cancer (CRC) is one of the most frequently encountered neoplasms in humans. The incidence of CRC has been increasing and new strategies for prevention, including chemoprevention, are required to lower its incidence and associated mortality. Metformin is a biguanide compound commonly used for the treatment of diabetes mellitus. Many recent basic research, epidemiological and clinical trial studies have indicated that metformin has benefits not only in diabetes treatment, but also in lowering the risk of developing cancer (including CRC). These studies indicate that metformin may be a candidate chemoprevention agent for CRC. This review article shall discuss the present evidence of metformin treatment and CRC, as well as outline our challenge in the investigation of metformin use in chemoprevention therapy for colorectal tumors.

Citing Articles

The colorectal cancer microenvironment: Preclinical progress in identifying targets for cancer therapy.

Meyiah A, Khan F, Alfaki D, Murshed K, Raza A, Elkord E Transl Oncol. 2025; 53:102307.

PMID: 39904281 PMC: 11846588. DOI: 10.1016/j.tranon.2025.102307.

Metformin: A Dual-Role Player in Cancer Treatment and Prevention.

Galal M, Al-Rimawi M, Hajeer A, Dahman H, Alouch S, Aljada A Int J Mol Sci. 2024; 25(7).

PMID: 38612893 PMC: 11012626. DOI: 10.3390/ijms25074083.

Metformin's role in lowering colorectal cancer risk among individuals with diabetes from the Southern Community Cohort Study.

Lawler T, Walts Z, Giurini L, Steinwandel M, Lipworth L, Murff H Cancer Epidemiol. 2024; 90:102566.

PMID: 38518387 PMC: 11108092. DOI: 10.1016/j.canep.2024.102566.

Current trends and future prospects of drug repositioning in gastrointestinal oncology.

Fatemi N, Karimpour M, Bahrami H, Zali M, Chaleshi V, Riccio A Front Pharmacol. 2024; 14:1329244.

PMID: 38239190 PMC: 10794567. DOI: 10.3389/fphar.2023.1329244.

Age-Specific Differences in the Risk of Colorectal Precursor Lesions Among Patients with Type 2 Diabetes Undergoing Surveillance Colonoscopy.

Mikaeel R, Edwards S, Winter J, Young J, Young G, Price T Asian Pac J Cancer Prev. 2023; 24(5):1769-1779.

PMID: 37247300 PMC: 10495897. DOI: 10.31557/APJCP.2023.24.5.1769.

References

Zakikhani M, Dowling R, Fantus I, Sonenberg N, Pollak M . Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res. 2006; 66(21):10269-73. DOI: 10.1158/0008-5472.CAN-06-1500. View

Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H . Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci. 2008; 99(11):2136-41. PMC: 11159964. DOI: 10.1111/j.1349-7006.2008.00933.x. View

Lin C, Huang H, Chu F, Fan H, Chen H, Chu D . Association between Gastroenterological Malignancy and Diabetes Mellitus and Anti-Diabetic Therapy: A Nationwide, Population-Based Cohort Study. PLoS One. 2015; 10(5):e0125421. PMC: 4433253. DOI: 10.1371/journal.pone.0125421. View

Zell J, Pelot D, Chen W, McLaren C, Gerner E, Meyskens F . Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas. Cancer Prev Res (Phila). 2009; 2(3):209-12. PMC: 2739681. DOI: 10.1158/1940-6207.CAPR-08-0203. View

Bekusova V, Patsanovskii V, Nozdrachev A, Anisimov V . Metformin inhibits development of colon malignant tumors induced by 1,2-dimethylhydrazine in rats. Dokl Biol Sci. 2016; 468(1):97-100. DOI: 10.1134/S0012496616030017. View

Sehdev A, Shih Y, Vekhter B, Bissonnette M, Olopade O, Polite B . Metformin for primary colorectal cancer prevention in patients with diabetes: a case-control study in a US population. Cancer. 2014; 121(7):1071-8. PMC: 4867231. DOI: 10.1002/cncr.29165. View

Drazen J . COX-2 inhibitors--a lesson in unexpected problems. N Engl J Med. 2005; 352(11):1131-2. DOI: 10.1056/NEJMe058038. View

Higurashi T, Hosono K, Takahashi H, Komiya Y, Umezawa S, Sakai E . Metformin for chemoprevention of metachronous colorectal adenoma or polyps in post-polypectomy patients without diabetes: a multicentre double-blind, placebo-controlled, randomised phase 3 trial. Lancet Oncol. 2016; 17(4):475-483. DOI: 10.1016/S1470-2045(15)00565-3. View

Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T . Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Cancer Prev Res (Phila). 2010; 3(9):1077-83. DOI: 10.1158/1940-6207.CAPR-10-0186. View

10.

Bird R . Role of aberrant crypt foci in understanding the pathogenesis of colon cancer. Cancer Lett. 1995; 93(1):55-71. DOI: 10.1016/0304-3835(95)03788-X. View

11.

Siegel R, Miller K, Jemal A . Cancer statistics, 2018. CA Cancer J Clin. 2018; 68(1):7-30. DOI: 10.3322/caac.21442. View

12.

Knapen L, Dittrich S, de Vries F, Starup-Linde J, Vestergaard P, Henry R . Use of biguanides and the risk of colorectal cancer: a register-based cohort study. Curr Drug Saf. 2013; 8(5):349-56. DOI: 10.2174/15680266113136660068. View

13.

Smiechowski B, Azoulay L, Yin H, Pollak M, Suissa S . The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus. Cancer Epidemiol Biomarkers Prev. 2013; 22(10):1877-83. DOI: 10.1158/1055-9965.EPI-13-0196. View

14.

Tseng C . Diabetes, metformin use, and colon cancer: a population-based cohort study in Taiwan. Eur J Endocrinol. 2012; 167(3):409-16. DOI: 10.1530/EJE-12-0369. View

15.

Ben Sahra I, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P . The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008; 27(25):3576-86. DOI: 10.1038/sj.onc.1211024. View

16.

Chan A, Ladabaum U . Where Do We Stand With Aspirin for the Prevention of Colorectal Cancer? The USPSTF Recommendations. Gastroenterology. 2015; 150(1):14-8. DOI: 10.1053/j.gastro.2015.11.018. View

17.

Takayama T, Nagashima H, Maeda M, Nojiri S, Hirayama M, Nakano Y . Randomized double-blind trial of sulindac and etodolac to eradicate aberrant crypt foci and to prevent sporadic colorectal polyps. Clin Cancer Res. 2011; 17(11):3803-11. DOI: 10.1158/1078-0432.CCR-10-2395. View

18.

Carretero J, Medina P, Blanco R, Smit L, Tang M, Roncador G . Dysfunctional AMPK activity, signalling through mTOR and survival in response to energetic stress in LKB1-deficient lung cancer. Oncogene. 2006; 26(11):1616-25. DOI: 10.1038/sj.onc.1209951. View

19.

Hay N . The Akt-mTOR tango and its relevance to cancer. Cancer Cell. 2005; 8(3):179-83. DOI: 10.1016/j.ccr.2005.08.008. View

20.

Suissa S, Azoulay L . Metformin and the risk of cancer: time-related biases in observational studies. Diabetes Care. 2012; 35(12):2665-73. PMC: 3507580. DOI: 10.2337/dc12-0788. View